LEXXW - Lexaria Receives Patent Protection in Japan
(TheNewswire)
New patent granted in Japan addsto existing patents in the EU, the U.S.,
India and Australia
Kelowna, British Columbia, July 13,2021 – LexariaBioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or“Lexaria”), a global innovator in drug delivery platforms,announces an additional expansion of its intellectual propertyportfolio with its first-ever patent granted in Japan.
The patent is titled “ Stableready-to-drink beverage compositions comprising lipophilic activeagents” and becomes the 20 th patent grantedto Lexaria, continuing to add to the Company’s considerableintellectual property portfolio.
“With our 20 th patent granted worldwide, Lexaria continuesto demonstrate the versatility of our DehydraTECH drug deliveryplatform, encouraging innovation in the consumable liquid categoryaround the world,” said Chris Bunka, CEO ofLexaria. “This new patent adds to our existing suite of grantedpatents spanning the EU, the U.S., India andAustralia, and continues to build value for Lexaria shareholders andclients.”
This is the third patent granted from Lexaria’s thirdpatent family. Lexaria’s patent application suite comprises a totalof 13 patent families. Active ingredients that may be used under this new patentinclude non-psychoactive cannabinoids and NSAIDS(e.g., acetylsalicylic acid, ibuprofen, diclofenac, indomethacin,piroxicam).
Lexaria has patent applications progressing incountries around the world with aggregate populations of nearly 4billion people and will report on further progress as informationbecomes available.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug deliverytechnology, DehydraTECH™, improves the way active pharmaceuticalingredients (APIs) enter the bloodstream by promoting healthier oralingestion methods and increasing the effectiveness of fat-solubleactive molecules, thereby lowering overall dosing. The Company’stechnology can be applied to many different ingestible productformats, including foods, beverages, oral suspensions, tablets, andcapsules. DehydraTECH has repeatedly demonstrated since 2016 withcannabinoids and nicotine the ability to increase bio-absorption by upto 5-10x, reduce time of onset from 1–2 hours to minutes, and maskunwanted tastes. DehydraTECH is planned to be further evaluated fororally administered bioactive molecules, including anti-virals,cannabinoids, vitamins, non-steroidal anti-inflammatory drugs(NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiplecompanies, including a world-leading tobacco producer for thedevelopment of smokeless, oral-based nicotine products, and for use inindustries that produce cannabinoid beverages, edibles, and oralproducts. Lexaria operates a licensed in-house research laboratory andholds a robust intellectual property portfolio with 19 patents grantedand approximately 60 patents pending worldwide. For more information,please visit www.lexariabioscience.com .
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press releaseincludes forward-looking statements. Statements as such term isdefined under applicable securities laws. These statements may beidentified by words such as "anticipate," "if,""believe," "plan," "estimate,""expect," "intend," "may,""could," "should," "will," and othersimilar expressions. Such forward-looking statements in this pressrelease include, but are not limited to, statements by the Companyrelating the Company’s ability to carry out research initiatives,receive regulatory approvals or grants, or experience positive effectsor results from any research or study. Such forward-looking statementsare estimates reflecting the Company's best judgment based uponcurrent information and involve a number of risks and uncertainties, and there can be no assurance that the Companywill actually achieve the plans, intentions, or expectations disclosedin these forward-looking statements. As such, you should not placeundue reliance on these forward-looking statements. Factors which could cause actualresults to differ materially from those estimated by the Companyinclude, but are not limited to, government regulation and regulatoryapprovals, managing and maintaining growth, the effect of adversepublicity, litigation, competition, scientific discovery, the patentapplication and approval process, potential adverse effects arisingfrom the testing or use of products utilizing the DehydraTECHtechnology, the Company’s ability to maintain existingcollaborations and realize the benefits thereof, delays orcancellations of planned R&D that could occur related to pandemicsor for other reasons, and other factors which may be identified fromtime to time in the Company's public announcements and periodicfilings with the U.S. Securities and Exchange Commission on EDGAR.There is no assurance that any of Lexaria’s postulated uses,benefits, or advantages for the patented and patent-pending technologywill in fact be realized in any manner or in any part. No statementherein has been evaluated by the Food and Drug Administration (FDA).Lexaria-associated products are not intended to diagnose, treat, cure,or prevent any disease. Any forward-looking statements contained inthis release speak only as of the date hereof, and the Companyexpressly disclaims any obligation to update any forward-lookingstatements contained herein, whether as a result of any newinformation, future events, changed circumstances, or otherwise,except as otherwise required by law.
Copyright (c) 2021 TheNewswire - All rights reserved.